Toll-like receptors: a target for many therapeutic applications

Research Areas

- Tool Development

At a Glance

- Status: Completed Consortium
- Year Launched: 2008
- Initiating Organization: Top Industry Pharma
- Initiator Type: Nonprofit foundation
- Location: Europe

Abstract

The broad interest for the role of the toll-like receptor (TLR) protein family has led to TI Pharma’s largest project, in which scientists from many different disciplines participate. Some work has been done on the development of tools that can modulate the function of TLRs. For instance, probiotics are being selected and small molecules are being generated that specifically affect TLR activity. Also, the possibilities for improvement of vaccination strategies using TLRs are being explored. Other researchers investigate the role of TLRs in specific disease areas such as cancer and cardiovascular and autoimmune disease. The knowledge obtained through this type of basic research together with the tools developed to interfere in TLR functioning will provide insight into the possibilities for further drug development based on TLR signaling.

Mission

The consortium’s goal is to identify and make TLR modulators and develop potentially relevant therapeutic applications.
Consortium History

The project duration was March 2008 to March 2012.

Sponsors & Partners

Homepage


Danone Research
ISA Pharmaceuticals
Leiden University
Leiden University Medical Center
Maastricht University
Radboud University Medical Center
TNO
University Medical Center Utrecht

Updated: 04/08/2016